Plainsboro, N.J.–Novo Nordisk has announced the U.S. launch of its NovoPen Echo® insulin delivery device. It is the first and only pen device available in this country with half-unit dosing and a memory function that records the dose and time passed since the last injection.
“We believe this pen can help patients fine-tune their dosing while offering added reassurance they are managing their diabetes appropriately,” said George McAvoy, vice president, NovoLog brand team at Novo Nordisk.
Because half-unit dose increments allow for finer adjustments, the device can be particularly useful to children, who often require more closely adjusted dosages. In addition, 12 removable skins are available for a customized look, including kid-friendly designs.
Jeff Hitchcock, founder of Children with Diabetes, said the device “is a welcome addition to the tools children with diabetes and their caregivers have available, especially when kids are away from home.”
The new pen is available to patients for use with NovoLog® PenFill® cartridges. Novo Nordisk has already launched NovoPen Echo® in Europe, Canada, and Israel.
For more information on Novo Nordisk products, visit www.novonordisk-us.com.